Heroin | Jotup

AITX's RADDOG™ 2LE Invited to Make its First Public Appearance at FOX’s ‘Stars on Mars’ Launch Event

Retrieved on:

Thursday, June 1, 2023

"We are very honored to have been invited to introduce RADDOG 2LE to the public at this exciting event," commented Reinharz.

Key Points:

"We are very honored to have been invited to introduce RADDOG 2LE to the public at this exciting event," commented Reinharz.
The RADDOG quadruped robots used in the show are similar to RADDOG 2LE units, which are specially designed for law enforcement.
The “Stars on Mars” RADDOGs perform the duties of the mission's security robots, as well as being companions to the crew members.
No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.

NIH STUDY FINDS PRENATAL SUBSTANCE EXPOSURE LINKED TO CHILD BEHAVIOR PROBLEMS

Retrieved on:

Wednesday, May 24, 2023

Duke University, The Journal of Pediatrics, Depression, Pediatrics, Methamphetamine, Anxiety, ECHO, Research, Tobacco, Heroin, Doctor of Philosophy, Bangladesh Technical Education Board, Mother, Cocaine, Risk, Biophysical environment, Passive-aggressive behavior, Dietary supplement, Birth control

DURHAM, N.C., May 24, 2023 /PRNewswire/ -- Prenatal exposure to tobacco, alcohol, and illegal drugs may increase a child's risk of displaying certain problem behaviors in later childhood, according to new research funded by the Environmental influences on Child Health Outcomes Program (ECHO) at the National Institutes of Health.

Key Points:

DURHAM, N.C., May 24, 2023 /PRNewswire/ -- Prenatal exposure to tobacco, alcohol, and illegal drugs may increase a child's risk of displaying certain problem behaviors in later childhood, according to new research funded by the Environmental influences on Child Health Outcomes Program (ECHO) at the National Institutes of Health.
However, ECHO researchers pointed out that not all children exposed to substances had behavioral problems.
"Our work shows that we may be able to identify children with certain behavioral challenges based on their mothers' prenatal substance use profiles," said Sarah Maylott, PhD of Duke University.
"With further research, clinicians and researchers could use these results to identify and support children at higher risk for behavior problems."

New Research Finds Dramatic Increase in Illegal Ketamine Seized by Authorities, Sparking Concern About Potential Dangers of Rising Recreational Use

Retrieved on:

Wednesday, May 24, 2023

"Unlike illegal ketamine years ago, most illegally obtained ketamine today is not pharmaceutical grade and is sold in powder form which may increase the risk that it contains other drugs such as fentanyl."

Key Points:

"Unlike illegal ketamine years ago, most illegally obtained ketamine today is not pharmaceutical grade and is sold in powder form which may increase the risk that it contains other drugs such as fentanyl."
He also warns that media and medical promotion of prescription ketamine in recent years is fueling black-market use and availability.
NDEWS continues to monitor the use and effects of ketamine and many novel drugs to alert the public about alarming trends in a timely manner.
The content of this research is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Aseptic Health Introduces SoRite DECON: The Revolutionary Decontaminant That Eradicates Fentanyl in 60 Seconds

Retrieved on:

Wednesday, May 24, 2023

NASHVILLE, Tenn., May 24, 2023 /PRNewswire-PRWeb/ -- Aseptic Health LLC, a renowned provider of innovative products for public safety, announces SoRite DECON, a new decontaminant that destroys narcotics like fentanyl, xylazine, and heroin in just 60 seconds. Unlike other decontaminants, SoRite DECON has been tested and verified to eradicate, not just neutralize, fentanyl at a third-party, Food and Drug Administration (FDA) and Drug Enforcement Agency (DEA) registered laboratory.

Key Points:

Aseptic Health has released SoRite DECON, a new decontaminant that destroys narcotics like fentanyl, xylazine, and heroin in just 60 seconds.
NASHVILLE, Tenn., May 24, 2023 /PRNewswire-PRWeb/ -- Aseptic Health LLC, a renowned provider of innovative products for public safety, announces SoRite DECON, a new decontaminant that destroys narcotics like fentanyl, xylazine, and heroin in just 60 seconds.
In response to this national epidemic, Aseptic Health LLC created SoRite DECON, a patent-pending decontaminant that destroys organic compounds and specifically narcotics like fentanyl, xylazine (also known as "tranq" or "zombie drug") and heroin in just 60 seconds.
SoRite DECON has been tested and verified to eradicate, not neutralize, fentanyl at a third-party, Drug Enforcement Agency (DEA) approved laboratory.

Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder

Retrieved on:

Tuesday, May 23, 2023

REMS, Mitigation, Pharmacy, Buprenorphine, Senior counsel, Health care, Opioid use disorder, OUD, SL, CIII, Heroin, Patient, Risk, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Vaccine, Pharmaceutical industry

PLYMOUTH MEETING, Pa., May 23, 2023 /PRNewswire/ -- Braeburn announces that the U.S. Food and Drug Administration (FDA) has approved BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a transmucosal buprenorphine-containing product. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support. BRIXADI is to be administered only by healthcare providers in a healthcare setting and will be available in the U.S. in September 2023.

Key Points:

Patients currently on a transmucosal buprenorphine-containing product can be switched to an equivalent dose of BRIXADI Weekly or Monthly.
BRIXADI is the first and only weekly and monthly subcutaneous injection for moderate to severe OUD and is the only buprenorphine injectable that utilizes FluidCrystal®* Injection Depot Technology.
"Today's FDA approval of BRIXADI is a significant step forward in the fight against OUD," said Mike Derkacz, President and CEO of Braeburn.
Additional medication options for opioid use disorder will support healthcare providers in addressing the needs of their patients with opioid use disorder."

Post-Accident Workforce Drug Positivity for Marijuana Reached 25-Year High in 2022, Quest Diagnostics Drug Testing Index Analysis Finds

Retrieved on:

Thursday, May 18, 2023

SECAUCUS, N.J., May 18, 2023 /PRNewswire/ -- The percentage of employees in the general U.S. workforce testing positive for marijuana following an on-the-job accident increased to its highest level in 25 years in 2022, according to a new analysis released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.

Key Points:

In 2022, the combined U.S. workforce urine drug positivity for all drugs persisted at 4.6% – the highest level in two decades.
While marijuana was the main driver of workforce positivity increases in the general U.S. workforce, amphetamines positivity also contributed to the increase.
Positivity for marijuana in the general U.S. workforce increased 10.3% (4.3% positivity in 2022 versus 3.9% positivity in 2021) and amphetamines positivity increased 15.4% (1.5% positivity in 2022 versus 1.3% positivity in 2021).
Positivity rates based on urine drug tests in certain drug categories for the federally mandated, safety-sensitive workforce increased in 2022.

Intelligent Bio Solutions Plans to Add Fentanyl Testing as it Further Enhances its Fingerprint-Based Drug Screening Solution

Retrieved on:

Tuesday, May 16, 2023

LC-MS/MS, Methamphetamine, Urine, Mass spectrometry, Fentanyl, Chromatography, Heroin, CDC, Death, Cocaine, Tandem mass spectrometry, Cannabis, Tranquilizer, Intelligence, Drug

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced plans to add the potent synthetic opioid drug, fentanyl, and fentanyl-adulterated street drugs, to the panel of substances detected by its lab-based confirmation testing using fingertip sweat collected by its proprietary Intelligent Fingerprinting Drug Screening System.

Key Points:

The Company is combatting this healthcare crisis by expanding the capabilities of its lab-based confirmation testing service to detect fentanyl and its related analogues in samples collected by its fingerprint-based drug testing system.
“By seeking to add fentanyl and other fentanyl-adulterated street drugs to our fingerprint-based lab-based confirmation drug testing panel, we are furthering our commitment to equipping workplaces to better combat the opioid issue.
We believe making drug testing for fentanyl non-invasive, quick, and hygienic is an important step towards addressing this crisis,” said Harry Simeonidis, President and CEO of Intelligent Bio Solutions.
Fingerprint testing provides a quick and dignified approach that is much more convenient than traditional urine or saliva drug testing methods.

River Oaks Treatment Center Warns of the Dangers of Delta-8-Tetrahydrocannabinol

Retrieved on:

Tuesday, May 16, 2023

Xylazine, Psychosis, K2, Cannabinoid, Aggression, History, Heroin, Delta-8-Tetrahydrocannabinol, Spice, Nature, CBD, Acid, Suicidal ideation, THC, Fentanyl, Pharmaceutical industry, Dietary supplement

RIVERVIEW, Fla., May 16, 2023 (GLOBE NEWSWIRE) -- Delta-8-Tetrahydrocannabinol (Delta-8 THC) is a widely sold product, but River Oaks Treatment Center, a leading provider of treatment for substance use and co-occurring mental health conditions, has issued a warning to consumers about the potential dangers associated with its consumption.

Key Points:

RIVERVIEW, Fla., May 16, 2023 (GLOBE NEWSWIRE) -- Delta-8-Tetrahydrocannabinol (Delta-8 THC) is a widely sold product, but River Oaks Treatment Center, a leading provider of treatment for substance use and co-occurring mental health conditions, has issued a warning to consumers about the potential dangers associated with its consumption.
“My main concern is that people buying these products are under the impression that it’s pure and natural when that certainly is not the case,” said Jeff Turiczek, CEO of River Oaks Treatment Center.
Instead, cannabidiol oil, or CBD oil, is exposed to a number of chemicals and processes resulting in a reaction that produces Delta-8 THC.
The active ingredient in just about every Delta-8 THC product sold to consumers – including tinctures and gummies – was produced in this manner.

Keep The Party Safe and AEG Presents: Rocky Mountains Join Forces to Save Lives Across Colorado

Retrieved on:

Tuesday, May 9, 2023

Keep The Party Safe, Colorado’s awareness effort to prevent fentanyl overdoses, and AEG Presents: Rocky Mountains, have launched a new partnership to help educate concertgoers in Colorado about the risk of fentanyl contaminated recreational drugs across the state.

Key Points:

Keep The Party Safe, Colorado’s awareness effort to prevent fentanyl overdoses, and AEG Presents: Rocky Mountains, have launched a new partnership to help educate concertgoers in Colorado about the risk of fentanyl contaminated recreational drugs across the state.
Through the new partnership, AEG Presents: Rocky Mountains and Keep the Party Safe will help ensure music and live-entertainment fans have the information they need for a safe and fun time, no matter the events they attend.
Launched in 2022 by the Colorado Consortium for Prescription Drug Abuse Prevention (Consortium), Keep The Party Safe educates and empowers audiences to take steps to protect themselves and their friends from overdose.
Keep The Party Safe education messages will be integrated into AEG venues and festivals in the Denver area:

World's First Xylazine ELISA by Randox Toxicology

Retrieved on:

Monday, May 8, 2023

Xylazine, Naloxone, Urine, Horse, Veterinary medicine, Toxicology, Heroin, ELISA, Evidence, DEA, Animal, Cocaine, Public security, Blood, Cattle, Fentanyl, Pharmaceutical industry, Drug

KEARNEYSVILLE, W.Va., May 8, 2023 /PRNewswire/ -- Randox Toxicology continues to lead in new test development within the ever-changing drugs of abuse market.

Key Points:

KEARNEYSVILLE, W.Va., May 8, 2023 /PRNewswire/ -- Randox Toxicology continues to lead in new test development within the ever-changing drugs of abuse market.
Their newly established ELISA test for xylazine is the first immunoassay test in the world for this drug of abuse.
Randox's newly established ELISA for xylazine is the first immunoassay test in the world for this drug of abuse.
The United States Drug Enforcement Authority (DEA) recently published a Public Safety alert about xylazine.